



Ultrasound Assisted Gene Therapy

TECHNOLOGY NUMBER: 2023-335



Technology ID

2023-335

Category

Therapeutics and Vaccines
Life Sciences

Inventor

Michael Passineau
Isabelle Lombaert

Further information

Megan Griffin
mrost@umich.edu

Innovation Partnerships Tech
Marketing Team

IPInventions@umich.edu

OVERVIEW

Ultrasound-assisted gene therapy using non-viral plasmid and microbubbles

- No immune response, allows multiple dosing tailored to patient needs
- Can treat genetic disorders, cancer, and radiation-induced hyposalivation

MODALITY

Minimally invasive gene delivery via FDA-approved ultrasound device and intravenous microbubbles

INDICATION

Genetic disorders, cancer therapy, and treatment of radiation-induced hyposalivation

BACKGROUND

Gene therapy has shown promise in treating various genetic disorders and certain cancers but often faces challenges related to delivery mechanisms, particularly those involving viral vectors, which can trigger immune responses and limit repeat dosing. Adenoassociated and adenoviral vectors, commonly used in gene therapy, have these limitations, making them less ideal for tailored treatments. Historically, non-viral plasmids have been explored but struggled with efficient delivery and cellular uptake. There is a critical need for a more effective, repeatable,

[View online](#)



and non-immunogenic delivery method. Ultrasound-assisted gene therapy offers a potential solution by using microbubbles to enhance plasmid delivery, thereby enabling more personalized therapeutic approaches.

INNOVATION

Investigators have created a product that combines a non-viral plasmid, an FDA-approved ultrasound machine, and microbubbles to achieve efficient gene delivery without eliciting an immune response. The plasmid is delivered using a GE ultrasound machine working in conjunction with FDA-approved Lantheus microbubbles. This method allows for multiple dosing, enabling tailored treatment protocols based on patient needs. Originally designed to treat radiation-induced hyposalivation, this approach has broader applications, including treating various genetic disorders and cancers. Key advancements include the non-immunogenic delivery system, the ability for repeat dosing, and a potential new patent surrounding these innovations. Real-world applications encompass personalized gene therapy for genetic disorders, cancer treatments, and conditions arising from radiation therapy, demonstrating a significant leap forward in gene therapy delivery methods.